Neuphoria Therapeutics Swings to $8.0M Loss as Cash Burn Intensifies in H1 FY2025

Neuphoria Therapeutics posted a net loss of $8.04 million for the six months ending December 31, 2025, compared with a $2.75 million loss in the same period a year earlier. The Delaware-based therapeutic company reported no revenue for the current period, while the prior-year period included $662,715 in revenue. Read more earnings reports.

Operating expenses climbed to $9.71 million from $7.93 million year-over-year. Research and development spending rose to $4.48 million from $3.64 million, while general and administrative costs remained minimal at $36,536 versus $33,806 in the prior period.

The company burned through $10.23 million in operating cash during the six-month period, up 31% from $7.79 million a year earlier. Neuphoria raised $17.92 million through financing activities, compared with an outflow of $338,900 in the prior period.

Cash and cash equivalents stood at $22.17 million as of December 31, 2025, up from $4.34 million at the end of the prior fiscal year. Total assets increased to $36.60 million from $28.59 million at June 30, 2025.

The company reported a quarterly net profit of $1.86 million for the three months ending December 31, 2025, reversing a $1.94 million loss in the same quarter a year earlier. The swing was driven by a sharp reduction in quarterly operating expenses, which fell to $4.06 million from $4.37 million.

Accounts receivable jumped to $1.11 million at period end from just $11,948 at mid-year. Total liabilities declined to $6.90 million from $9.59 million six months prior, driven by reductions in accounts payable and accrued liabilities.

Stockholders' equity rose to $29.70 million from $19.00 million at June 30, 2025, reflecting the equity financing and accumulated losses. The company reported 5.38 million common shares outstanding at period end, up from 1.98 million shares six months earlier.

For the six-month period, basic loss per share was $2.37 compared with a loss of $1.91 per share in the prior year. The company reported a basic profit of $0.41 per share for the December quarter versus a loss of $1.23 per share a year earlier.